Peter C. Adamson
- Affiliations
- Administrative Units:
Clinical Translational Research
Pediatric oncology
Clinical pharmacology
Relapsed pediatric malignancies
Dr. Adamson's laboratory focuses on the clinical pharmacology of new drugs for childhood cancer.
My primary research focus has been on pediatric cancer drug development, specifically early phase clinical trails and clinical pharmacologic studies. Until 2008 I served as Chair of the Children's Oncology Group (COG) Developmental Therapeutics Programs and Principal Investigator of the COG Phase 1 Consortium, and in 2011 became Chair of the Children's Oncology Group. Prior to becoming the Director of the Office for Clinical and Translational Research at CHOP, I was the Program Director of the General Clinical Research Center (GCRC) and Principal Investigator of its NICHD funded Pediatric Pharmacology Research Unit (PPRU). My laboratory focuses on the clinical pharmacology of new drugs for childhood cancer using an integrated approach that incorporates preclinical studies in both in vitro and animal models, and clinical trials with clinical pharmacokinetic-pharmacodynamic-pharmacogenetic studies in pediatric patients. As Director of the Office for Clinical and Translational Research at CHOP, I work with clinical and translational investigators in identifying scientific opportunities and in forging productive collaborations throughout CHOP and the University of Pennsylvania.
- Associate Professor of Pediatrics at the Children's Hospital of Philadelphia (1999 – 2006)
- Associate Professor of Pharmacology at University of Pennsylvania School of Medicine (2004 – 2009)
- Professor of Pediatrics in Pharmacology at University of Pennsylvania School of Medicine (2009– present)
- Professor of Pediatrics at the Children's Hospital of Philadelphia (2006– present)
- M.D., Medicine, Cornell University Medical College, New York, NY (1984)
- B.A., Chemistry, Wesleyan University, Middletown, CT (1980)
- Glauser, T. A., Cnaan, A., Shinnar, S., Hirtz, D. G., Dlugos, D., Masur, D., Clark, P. O., Adamson, P. C., for the Childhood Absence Epilepsy Study, Team. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: Initial monotherapy outcomes at 12 months. Epilepsia. Vol 54(1) . 2013:141-155.
- Mosse, Y. P., Lipsitz, E., Fox, E., Teachey, D. T., Maris, J. M., Weigel, B., Adamson, P. C., Ingle, M. A., Ahern, C. H., Blaney, S. M.. Pediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective small-molecule inhibitor of Aurora kinase A: a Children''s Oncology Group Phase I Consortium study. Clinical Cancer Research. Vol 18(21) . 2012:6058-64.
- Malempati, S., Weigel, B., Ingle, A. M., Ahern, C. H., Carroll, J. M., Roberts, C. T., Reid, J. M., Schmechel, S., Voss, S. D., Cho, S. Y., Chen, H. X., Krailo, M. D., Adamson, P. C., Blaney, S. M.. Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children''s Oncology Group. Journal of Clinical Oncology. Vol 30(3) . 2012:256-62.
- Dubois, S. G., Shusterman, S., Ingle, A. M., Ahern, C. H., Reid, J. M., Wu, B., Baruchel, S., Glade-Bender, J., Ivy, P., Grier, H. E., Adamson, P. C., Blaney, S. M.. Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children''s oncology group study. Clinical Cancer Research. Vol 17(15) . 2011:5113-22.
- Dubois, S. G., Shusterman, S., Ingle, A. M., Ahern, C. H., Reid, J. M., Wu, B., Baruchel, S., Glade-Bender, J., Ivy, P., Grier, H. E., Adamson, P. C., Blaney, S. M.. Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children''s oncology group study. Clinical Cancer Research. Vol 17(15) . 2011:5113-22.
- Berg, S. L., Cairo, M. S., Russell, H., Ayello, J., Ingle, A. M., Lau, H., Chen, N., Adamson, P. C., Blaney, S. M.. Safety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: a Children''s Oncology Group Phase I Consortium report. Journal of Clinical Oncology. Vol 29(3) . 2011:316-23.
- Aplenc, R., Blaney, S. M., Strauss, L. C., Balis, F. M., Shusterman, S., Ingle, A. M., Agrawal, S., Sun, J., Wright, J. J., Adamson, P. C.. Pediatric Phase I Trial and Pharmacokinetic Study of Dasatinib: A Report From the Children''s Oncology Group Phase I Consortium. Journal of Clinical Oncology. Vol 29(7) . 2011:839-44.
- Glauser, T. A., Cnaan, A., Shinnar, S., Hirtz, D. G., Dlugos, D., Masur, D., Clark, P. O., Capparelli, E. V., Adamson, P. C.. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. New England Journal of Medicine. Vol 362(9) . 2010:790-9.
- Widemann Brigitte C, Balis Frank M, Kim AeRang, Boron Matthew, Jayaprakash Nalini, Shalabi Aiman, O'Brien Michelle, Eby Michelle, Cole Diane E, Murphy Robert F, Fox Elizabeth, Ivy Percy, Adamson Peter C. Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Vol 28(25) . 2010 Sep:3979-86.
- Malempati, S., Weigel, B., Ingle, A. M., Ahern, C. H., Carroll, J. M., Roberts, C. T., Reid, J. M., Schmechel, S., Voss, S. D., Cho, S. Y., Chen, H. X., Krailo, M. D., Adamson, P. C., Blaney, S. M.. Phase I/II Trial and Pharmacokinetic Study of Cixutumumab in Pediatric Patients With Refractory Solid Tumors and Ewing Sarcoma: A Report From the Children''s Oncology Group. Journal of Clinical Oncology. 2011.